In light of a recent case, David Prange and Christopher Pinahs, from USA-based law firm Robins Kaplan, provide an Expert View piece containing potentially crucial insights into improving trade secret protection. 19 December 2017
Swiss pharma giant Novartis intends to localize up to 40 drugs at its Novartis-Neva plant in the Russian St Petersburg region, according to recent statements of vice governor of St Petersburg Sergey Movchan. 19 December 2017
The final Special Report of 2017 comes from Scott Pescatore, the Europe region general manager for rare diseases at Novartis Oncology, and is an overview of how progress has been made, and how more can be achieved, in the orphan medicines space. 19 December 2017
Robert Stewart is to leave his role as chief operating officer of Ireland-incorporated drugmaker Allergan to take the top job at Amneal Pharmaceuticals. 18 December 2017
Pharmaceutical companies in India have been providing scientific insights into the genetic causes and biological processes underlying neurodegenerative diseases, reports The Pharma Letter’s India correspondent. 18 December 2017
In a candid admission, privately-owned German pharma major Boehringer Ingelheim has said that conflicting views over strategy are behind the departure of one of its most senior executives. 18 December 2017
In today’s world, cheap insults from people in high places – whether justified and evidence-backed or not – can do harm to the reputation and market value of pharma firms that can be difficult to repair. 15 December 2017
Changes to Japan’s drug reimbursement system care are inevitable. The only questions are the extent of changes and when they will be implemented. We should have answers to these questions at year end so they can be implemented in April 2018, says P Reed Maurer, long-time Japan pharma watcher and president of International Alliances Limited in his regular column for The Pharma Letter. 15 December 2017
Chinese biologics services provider WuXi Biologics (HK: 2269) recently started the operation of a new current Good Manufacturing Practices (cGMP) facility for biologics manufacturing in Wuxi, Jiangsu province, writes Wang Fangqing, The Pharma Letter’s local correspondent. 15 December 2017
Dr Nicola Davies discusses the US Food and Drug Administration’s (FDA) new framework on regenerative medicine that is aimed at spurring innovation in transformative products while ensuring safety and efficacy. 15 December 2017
In an Expert View piece, Rosanne Kay, partner at international law firm Reed Smith, considers when to escalate matters to an internal investigation, and how best to carry them out. 14 December 2017
It’s impossible to imagine how many lives antibiotics have saved since penicillin was first synthesized by Alexander Fleming in 1928 - certainly tens, if not hundreds of millions. 14 December 2017
Clinical-stage US biotech Provectus Biopharmaceuticals has reached a settlement with the US Securities and Exchange Commission (SEC) in connection with investigations relating to two former executives and the company. 13 December 2017
Mundipharma network of independent associated companies has appointed Alberto Martinez as president and chief executive of Mundipharma International, with immediate effect. 13 December 2017
Swiss pharmaceutical giant Roche, which invested 1.5 billion roubles ($25 million) in the localization of the production of its anti-cancer drug Gaziva/Gazyvaro (obinutuzumab) in Russia in order to participate in public procurements, may not implement its plans, reports The Pharma Letter’s local correspondent. 12 December 2017
It is the third-most common disorder in the world. In the USA, close to 38 million people suffer from it. Globally, the number is a whopping 1 billion. We are talking about migraine, also often referred to as ‘super headaches’ — a condition more prevalent than diabetes, epilepsy, and asthma combined. 11 December 2017
Drug imports by Russia for the period of January-September of 2017 grew for the first time since 2014 and amounted to 108.700 tonnes, which is 6.5% more than in the same period a year ago. 11 December 2017
The occasion of World AIDS Day was as good as any for India to launch a National Strategic Plan 2017-24, aimed at eradicating HIV/ AIDS by 2030. The country has over 2.1 million people living with HIV, the third largest number of people with HIV in the world, reports The Pharma Letter’s India correspondent. 8 December 2017
Last week, the UK government published its latest annual update on its five year strategy to combat antimicrobial resistance (AMR). AMR, widely accepted as one of the major global challenges of the 21st century, is currently implicated in around 700,000 deaths worldwide, including 50,000 in the USA and Europe alone. 7 December 2017
Oligonucleotide therapeutics are rapidly emerging as a promising class of drugs capable of addressing a variety of genetic and complex diseases by targeting RNA sequences.1 16 September 2024
The protection of intellectual property (IP) rights of foreign pharmaceutical companies in Russia remains complex situation, according to recent statements by Konstantin Panurovsky, legal director of AstraZeneca’s Russian subsidiary, reports The Pharma Letter’s local correspondent. 13 September 2024
The Russian Ministry of Health wants to speed registration of drugs that are not localized in the Russian Federation at the time of the application submitted by domestic pharmaceutical companies, explaining such changes by "unpredictable geopolitical situation," reports The Pharma Letter’s local correspondent. 12 September 2024
NewCo, a relatively new business model that involves a joint venture (JV) between a biotech and a group of investors to bring the biotech’s promising assets to the global market, is gaining popularity among Chinese biotechs, who traditionally rely on out-licensing deals to capitalize assets, s 11 September 2024
The upcoming European Society for Medical Oncology (ESMO) Congress 2024 should provide a reminder—if it were needed—of the pace of innovation in the development of new medicines for cancer. 10 September 2024
A significant drop has been noticed in the prices of active pharmaceutical ingredients (APIs), bringing much-needed relief to the pharmaceutical industry and potentially translating to lower drug costs for consumers. 9 September 2024
Amid an explosion in investment and development milestones seen over the past decade, the age of radiopharmaceuticals as both diagnostics and as therapeutics is very much arriving. 5 September 2024
German pharma major Bayer has filed a lawsuit against the Russian drugmaker Promomed to protect the patent rights for Xarelto (rivaroxaban), its treatment for stroke prevention which is the best-selling drug in the Russian market at present, The Pharma Letter’s local correspondent reports. 2 September 2024
In a major crackdown, the Indian government has imposed an immediate ban on 156 fixed-dose combination (FDC) drugs, including commonly used antibiotics, pain relievers,and multivitamins. 27 August 2024
Russia plans to create conditions for a significant increase of domestic production of anti-Rhesus immunoglobulin drugs after a sharp decrease of their imports to the local market this year, reports The Pharma Letter’s local correspondent. 22 August 2024
Accord Healthcare might not be as well-known as certain preeminent pharma corporations in the UK and Europe, but you would struggle to find any company making a greater contribution to the production and supply of medicines across the continent. 14 August 2024
The shortage of drugs in Russia is deepening, and is currently being observed in almost 70 regions throughout the country and forcing the local state to consider ways to resume stable supplies to local market, reports The Pharma Letter’s local correspondent. 13 August 2024
US biotech major Biogen is disputing the launch of a Russian generic of Spinraza (nusinersen), a drug, which is used to treat spinal muscular atrophy (SMA), reports The Pharma Letter’s local correspondent. 7 August 2024
CytoReason’s $80 million venture round may not have been the biggest in July, but it is one of a growing number of investor bets on AI powered drug discovery this year. 7 August 2024
Domestic drugs and foreign drugs, the production of which is localized in Russia, will be given a priority when included in the list of vital and essential drugs (VED) and expensive drugs, according to a recent resolution signed by the Russian government, The Pharma Letter’s local correspondent reports. 1 August 2024